Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or
BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have
activity in patients with homologous recombination defects (HRD).
BRCA 1/2 plays an essential role in homologous recombination repair and breast cancer
patients with BRCA 1/2 germline mutation have homologous recombination defects (HRD). Besides
BRCA1 or BRCA2 germline mutation, a proportion of breast cancer is characterized as having
HRD through germline mutation, somatic mutation, and epigenetic alteration of other
homologous recombination repair (HRR) genes (which includes but are not limited to ATM,
BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L)
(5). It is speculated that tumor with HRD may have clinical benefit from PARP inhibitor.
However, the efficacy of talazoparib in advanced breast cancer with HRD is not known. The
primary purpose of the present study is to evaluate the efficacy of talazoparib in breast
cancer with HRD.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.